STOCK TITAN

[Form 4] Lifevantage Corp Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4

Kristen Cunningham, Chief Sales Officer and director at Lifevantage Corp (LFVN), reported an insider sale on 10/01/2025. The filing shows she sold 1,720 shares of Lifevantage common stock at a price of $9.56 per share, leaving her with 136,986 shares owned directly. The Form 4 was signed by a power of attorney on 10/03/2025. This report discloses a routine officer sale and the resulting post-transaction ownership.

Kristen Cunningham, Chief Sales Officer e direttrice di Lifevantage Corp (LFVN), ha riferito una vendita interna il 10/01/2025. La dichiarazione mostra che ha venduto 1.720 azioni di azioni ordinarie Lifevantage a un prezzo di $9.56 per azione, rimanendo con 136.986 azioni possedute direttamente. Il Form 4 è stato firmato da una procura il 10/03/2025. Questo rapporto rende nota una vendita ordinaria da parte di un dirigente e la proprietà post-trasazione risultante.

Kristen Cunningham, Directora de Ventas y directora en Lifevantage Corp (LFVN), informó una venta interna el 01/10/2025. La declaración muestra que vendió 1.720 acciones de Lifevantage a un precio de $9.56 por acción, quedando con 136.986 acciones poseídas directamente. El Formulario 4 fue firmado por un poder el 03/10/2025. Este informe divulga una venta de rutina por parte de un alto cargo y la propiedad post-transacción resultante.

Kristen Cunningham, Lifevantage Corp (LFVN) 최고영업책임자 겸 이사로, 2025년 10월 1일에 내부자 매도를 보고했습니다. 제출 문서에 따르면 그녀는 Lifevantage 보통주를 1,720주 매도했고 주당 가격은 $9.56였으며, 직접 소유하고 있던 주식은 136,986주로 남았습니다. Form 4는 2025년 10월 3일에 위임장으로 서명되었습니다. 이 보고서는 임원 매도와 거래 후의 보유 현황을 공개합니다.

Kristen Cunningham, directrice des ventes et administratrice chez Lifevantage Corp (LFVN), a signalé une vente d’initié le 01/10/2025. Le dépôt indique qu’elle a vendu 1 720 actions de Lifevantage à un prix de 9,56 $ par action, lui laissant 136 986 actions détenues directement. Le Formulaire 4 a été signé par une procuration le 10/03/2025. Ce rapport divulgue une vente routinière par un dirigeant et la propriété post-transaction qui en résulte.

Kristen Cunningham, Chief Sales Officer und Direktorin bei Lifevantage Corp (LFVN), meldete einen Insider-Verkauf am 01.10.2025. Die Einreichung zeigt, dass sie 1.720 Aktien der Lifevantage-Stammaktie zu einem Preis von 9,56 $ pro Aktie verkauft hat und direkt weiterhin 136.986 Aktien besitzt. Das Formular 4 wurde am 03.10.2025 durch eine Vollmacht unterzeichnet. Dieser Bericht gibt einen routinemäßigen Verkauf eines Offiziers und das daraus resultierende Eigentum nach der Transaktion bekannt.

كريستين كنجنهام، المدير التنفيذي للمبيعات والمدير في Lifevantage Corp (LFVN)، أبلغت عن بيع داخلي في 10/01/2025. تُظهر الإيداع أنها باعَت 1,720 سهمًا من أسهم Lifevantage العادية بسعر $9.56 للسهم، مما ترك لديها 136,986 سهمًا مملوكة مباشرة. تم توقيع النموذج 4 بواسطة توكيل في 10/03/2025. يكشف هذا التقرير عن بيع روتيني من قبل مسؤول تنفيذي وملكيتهم بعد المعاملة.

Kristen Cunningham,Lifevantage Corp(LFVN)的首席销售官兼董事,报告了在 2025/10/01 的一笔内幕交易。披露显示她以每股 $9.56 的价格出售 Lifevantage 普通股 1,720 股,直接持有的股份剩余为 136,986 股。Form 4 于 2025/10/03 由授权书签署。该报告披露了高管的日常出售以及交易后的持股情况。

Positive
  • None.
Negative
  • None.

Kristen Cunningham, Chief Sales Officer e direttrice di Lifevantage Corp (LFVN), ha riferito una vendita interna il 10/01/2025. La dichiarazione mostra che ha venduto 1.720 azioni di azioni ordinarie Lifevantage a un prezzo di $9.56 per azione, rimanendo con 136.986 azioni possedute direttamente. Il Form 4 è stato firmato da una procura il 10/03/2025. Questo rapporto rende nota una vendita ordinaria da parte di un dirigente e la proprietà post-trasazione risultante.

Kristen Cunningham, Directora de Ventas y directora en Lifevantage Corp (LFVN), informó una venta interna el 01/10/2025. La declaración muestra que vendió 1.720 acciones de Lifevantage a un precio de $9.56 por acción, quedando con 136.986 acciones poseídas directamente. El Formulario 4 fue firmado por un poder el 03/10/2025. Este informe divulga una venta de rutina por parte de un alto cargo y la propiedad post-transacción resultante.

Kristen Cunningham, Lifevantage Corp (LFVN) 최고영업책임자 겸 이사로, 2025년 10월 1일에 내부자 매도를 보고했습니다. 제출 문서에 따르면 그녀는 Lifevantage 보통주를 1,720주 매도했고 주당 가격은 $9.56였으며, 직접 소유하고 있던 주식은 136,986주로 남았습니다. Form 4는 2025년 10월 3일에 위임장으로 서명되었습니다. 이 보고서는 임원 매도와 거래 후의 보유 현황을 공개합니다.

Kristen Cunningham, directrice des ventes et administratrice chez Lifevantage Corp (LFVN), a signalé une vente d’initié le 01/10/2025. Le dépôt indique qu’elle a vendu 1 720 actions de Lifevantage à un prix de 9,56 $ par action, lui laissant 136 986 actions détenues directement. Le Formulaire 4 a été signé par une procuration le 10/03/2025. Ce rapport divulgue une vente routinière par un dirigeant et la propriété post-transaction qui en résulte.

Kristen Cunningham, Chief Sales Officer und Direktorin bei Lifevantage Corp (LFVN), meldete einen Insider-Verkauf am 01.10.2025. Die Einreichung zeigt, dass sie 1.720 Aktien der Lifevantage-Stammaktie zu einem Preis von 9,56 $ pro Aktie verkauft hat und direkt weiterhin 136.986 Aktien besitzt. Das Formular 4 wurde am 03.10.2025 durch eine Vollmacht unterzeichnet. Dieser Bericht gibt einen routinemäßigen Verkauf eines Offiziers und das daraus resultierende Eigentum nach der Transaktion bekannt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Cunningham Kristen

(Last) (First) (Middle)
3300 TRIUMPH BLVD, SUITE 700

(Street)
LEHI UT 84043

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Lifevantage Corp [ LFVN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Sales Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/01/2025 F 1,720 D $9.56 136,986 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Remarks:
/s/ Alissa Neufeld, Power of Attorney for Kristen Cunningham 10/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Lifevantage insider Kristen Cunningham do on 10/01/2025 (LFVN)?

She sold 1,720 shares of Lifevantage common stock at $9.56 per share on 10/01/2025.

What is Kristen Cunningham's role at Lifevantage (LFVN)?

She is listed as a Director and the company's Chief Sales Officer.

How many Lifevantage shares did Kristen Cunningham own after the sale?

Following the reported transaction she beneficially owned 136,986 shares directly.

When was the Form 4 signed for Kristen Cunningham's transaction?

The Form 4 bears a signature by power of attorney dated 10/03/2025.

What price did the insider sale occur at for LFVN?

The reported sale price was $9.56 per share.
Lifevantage Corp

NASDAQ:LFVN

LFVN Rankings

LFVN Latest News

LFVN Latest SEC Filings

LFVN Stock Data

120.69M
10.54M
16.79%
65.65%
19.95%
Packaged Foods
Pharmaceutical Preparations
Link
United States
LEHI